You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
|
|---|---|
| Published in |
Respiratory Research, December 2011
|
| DOI | 10.1186/1465-9921-12-156 |
| Pubmed ID | |
| Authors |
Anthony D'Urzo, Gary T Ferguson, Jan A van Noord, Kazuto Hirata, Carmen Martin, Rachael Horton, Yimeng Lu, Donald Banerji, Tim Overend |
| Abstract |
NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 1% |
| Switzerland | 1 | <1% |
| Portugal | 1 | <1% |
| Australia | 1 | <1% |
| Peru | 1 | <1% |
| Unknown | 138 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 27 | 19% |
| Researcher | 16 | 11% |
| Student > Bachelor | 16 | 11% |
| Student > Master | 14 | 10% |
| Professor > Associate Professor | 11 | 8% |
| Other | 34 | 24% |
| Unknown | 26 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 70 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 8% |
| Agricultural and Biological Sciences | 9 | 6% |
| Nursing and Health Professions | 7 | 5% |
| Social Sciences | 3 | 2% |
| Other | 15 | 10% |
| Unknown | 28 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2013.
All research outputs
#3,187,929
of 25,373,627 outputs
Outputs from Respiratory Research
#387
of 3,062 outputs
Outputs of similar age
#23,923
of 249,661 outputs
Outputs of similar age from Respiratory Research
#5
of 76 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,062 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,661 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.